CN105616753A - Application of Qianlieshule preparation in preparation of drug for treating chronic atrophic gastritis and complications thereof - Google Patents
Application of Qianlieshule preparation in preparation of drug for treating chronic atrophic gastritis and complications thereof Download PDFInfo
- Publication number
- CN105616753A CN105616753A CN201510989298.8A CN201510989298A CN105616753A CN 105616753 A CN105616753 A CN 105616753A CN 201510989298 A CN201510989298 A CN 201510989298A CN 105616753 A CN105616753 A CN 105616753A
- Authority
- CN
- China
- Prior art keywords
- preparation
- qianlieshule
- apply
- parts
- atrophic gastritis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/21—Amaranthaceae (Amaranth family), e.g. pigweed, rockwort or globe amaranth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/29—Berberidaceae (Barberry family), e.g. barberry, cohosh or mayapple
- A61K36/296—Epimedium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/68—Plantaginaceae (Plantain Family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention provides application of a Qianlieshule preparation in preparation of a drug for treating chronic atrophic gastritis and complications thereof. The Qianlieshule preparation is prepared from herba epimedii, milkvetch roots, herba plantaginis, pollen typhae and radix cyathulae and can effectively treat the chronic atrophic gastritis and the complications thereof, wherein the complications comprise gastrorrhagia, anemia and a gastric ulcer.
Description
Invention field
The present invention relates to the new application of 'Qianlieshule ', preparing, particularly to 'Qianlieshule ', the application treated in chronic atrophic gastritis and complication medicine thereof.
Background technology
Atrophic gastritis is also referred to as chronic atrophic gastritis, and with gastric epithelial and body of gland atrophy, decreased number, gastric mucosa is thinning, and mucosa basic unit thickens, or accompanies gland metaplasia and intestinal gland metaplasia or the chronic digestive system disease having atypical hyperplasia to be feature. Often show as epigastrium dull pain, distension, belch, inappetence, or become thin, anemia etc., without specificity. It is a kind of many paathogenic factors disease and precancerous lesion.
'Qianlieshule ' is mainly made up of Herba Epimedii, the Radix Astragali, Herba Plantaginis, Pollen Typhae and Radix Cyathulae; Have and tonify Qi of the kidney, effect of Huayu Tonglin. Cure mainly kidney spleen double; two empty, qi depression to blood stasis, prostatic hyperplasia, chronic prostatitis; Complexion is shaken white, and spiritlessness and weakness, waist knee joint is sluggish, sagging distention in the smaller abdomen, and urine is not well, and drop does not go out, or frequent micturition, urgent micturition, Urethra astringent pain. Inventor finds in clinical studies, and 'Qianlieshule ' also has the effect of certain treatment chronic atrophic gastritis and complication thereof.
Summary of the invention
It is an object of the invention to provide 'Qianlieshule ' application in preparation treatment chronic atrophic gastritis and complication medicine thereof.
The present invention is achieved through the following technical solutions. 'Qianlieshule ' application in preparation treatment chronic atrophic gastritis and complication medicine thereof.
Aforesaid application, described complication includes gastrorrhagia, anemia or gastric ulcer.
In aforesaid application, described 'Qianlieshule ' calculates according to composition by weight, is mainly made up of Herba Epimedii 90-110 part, Radix Astragali 40-60 part, Herba Plantaginis 40-60 part, Pollen Typhae 27.5-47.5 part and Radix Cyathulae 11.5-13.5 part.
In aforesaid application, described 'Qianlieshule ' calculates by weight, is mainly made up of Herba Epimedii 100 parts, the Radix Astragali 50 parts, Herba Plantaginis 50 parts, Pollen Typhae 37.5 parts and Radix Cyathulae 12.5 parts.
In aforesaid application, described 'Qianlieshule ' is prepared: take each medicine, adds one or more pharmaceutically acceptable adjuvants, according still further to the conventional method of pharmaceutical field, prepares into acceptable dosage form in field of medicaments.
In aforesaid application, described dosage form includes oral formulations, ejection preparation or external preparation.
In aforesaid application, described oral formulations includes granule, oral liquid, capsule, pill or tablet.
In aforesaid application, the preparation method of described granule is: takes Herba Epimedii, Radix Astragali car, front grass, Pollen Typhae and Radix Cyathulae and adds water, decoct 2 times, 2 hours first times, second time 1 hour, merging filtrate, it is the extractum of 1.14-1.17 that filtrate is condensed into relative density when 60-70 DEG C, cooling, filters, the starch airpillow-dry adding the amount of making 15% is granulated, and to obtain final product.
In order to make those of ordinary skill in the art be better understood from the present invention, the purposes of the present invention is expanded on further below by way of experiment and embodiment:
Experimental example 1. pharmacological experiment study
1 materials and methods
1.1 experiment materials
1.1.1 medicine: 'Qianlieshule ' (is prepared according to the preparation method of embodiment 1).
1.1.2 animal SD rat totally 100, are provided by Guiyang Medical College animal center.
1.2 methods
1.2.1 the making of atrophic gastritis model adopts active immunity 2 times, simultaneously the method for bile and the continuous 70d of hot water gavage. Active immunity: every rat skin lower injection adjuvant antigen (being made into Emulsion with 1: 1 with the normal saline homogenate of gastric mucosa of rat of the same race and Freund adjuvant) 0.3mL, after 1 month, duplicate injection 1 time. Bile gavage: while rat carries out active immunity injection, with without suppurative inflammation patient's bile by 12.5mL/kg body weight gavage (before gavage, 4h stops eating, and freely drinks water), every day 1 time, continuous 70d. Hot water gavage: while carrying out above-mentioned 2, with 50 DEG C of hot water 20mL/kg body weight to rat oral gavage, every day 1 time, continuous 70d. After above integrated treatment, rat atrophic Factor in Gastritis model can be caused, for experiment.
1.2.2 packet and medication SD rat 100. Male and female half and half, are divided into the large and small dosage group of normal group, prostate disease, vitacoenzyme matched group, normal saline group, often group 20. Normal group fills normal saline 12mL/kg, every day 1 time, continuous 111d. All the other 4 groups all make atrophic gastritis model with preceding method after, by medicine given below and dosage gavage every day 1 time, continuous 45d. Heavy dose of group: prostate disease aqueous solvent, 6g/kg body weight (is equivalent to people's quantity equivalent 4 times). Small dose group: prostate disease aqueous solvent, 2g/kg body weight. Vitacoenzyme matched group: vitacoenzyme 0.5g/kg body weight (is equivalent to people's quantity equivalent 2 times). Normal saline group: normal saline, 12mL/kg body weight.
1.2.3 more than observation index 5 groups during being administered, observe ordinary circumstance and body weight change, administration is anesthetized with ether rat after terminating. Solution cuts stomach, measures Stomach stomy with the micro-glass electrode acidometer of pH-3C type. Drawing materials at lesser gastric curvature, paries anterior gastricus and paries posterior gastricus respectively, make paraffin section, HE dyes. Every rat pathology cuts 3, at OLYMPUS type basis of microscopic observation, images by constant position, the photo of every each take 3 amplification 400 times of cutting into slices. By point analysis method, measure gastric mucosa parietal cell body density, enter data in microcomputer and do t inspection by MDRPHUMETPY routine processes.
2 results
2.1 ordinary circumstance the normal group mental status, active situation, hair luster degree and appetite in whole experimentation are superior to other each group. All the other 4 groups during moulding, ordinary circumstance is all more poor, and order is heavy dose of group, small dose group, vitacoenzyme matched group, normal saline group.
2.2 body weight change
Body weight change before and after mice administration respectively organized by table 1
* P < 0.05 is compared with normal saline group,**P < 0.01,***P < 0.001; Compare with vitacoenzyme matched group��P < 0.05
Table 1 is visible, the large and small dosage group body weight of prostate disease after administration the 26th day just apparently higher than normal saline group (P < 0.01), obviously higher than normal saline group (P < 0.001) and vitacoenzyme group (P < 0.05) when the 45th day. Show that the body weight of atrophic gastritis rat model is had good facilitation by this product.
2.3 experimental rat Stomach stomy, parietal cell body density (p parietal cell body density) change
Stomach stomy respectively organized by table 2, the change of parietal cell body density is compared
Compare with saline control group*P < 0.05,*P < 0.001; Compare with vitacoenzyme matched group��P < 0.05,����P<0.001
Table 2 is visible, and the large and small dosage group of prostate disease compares with normal saline group, and pH value reduces, and parietal cell body density increases, and difference is very significant (P < 0.001); Compare pH value to reduce with vitacoenzyme matched group, have significant difference (P < 0.05) or significant differences (P < 0.001).
3 discuss
The pathological change of chronic atrophic gastritis, main manifestations is that parietal cell, chief cell, G cell, mucosal cell damage reduce. Clinical there is low acid or acid deficient and low gastric juice syndrome group. This experiment is using the parietal cell of Major Secretory gastric acid and corresponding value of gastric intramucosal pH as research emphasis, application cell form solid meterological way, determine the body density of parietal cell, parietal cell number change and the gastric acid secretion situation of chronic withering property gastritis sufferer's gastric mucosa can be reflected more objectively. Prostate disease can make parietal cell increasing number, and micro-acid secretory volume increases, and appetite is improved, and body weight increases, thus reaching the purpose for the treatment of chronic atrophic gastritis.
Compared with prior art, 'Qianlieshule ' of the present invention can treat chronic atrophic gastritis and complication thereof. 'Qianlieshule ' can make parietal cell increasing number, and micro-acid secretory volume increases, and appetite is improved, and body weight increases. Reach goal of the invention.
Detailed description of the invention
Embodiment 1.
Formula: Herba Epimedii 100g, Radix Astragali 50g, Herba Plantaginis 50g, Pollen Typhae 37.5g and Radix Cyathulae 12.5g.
Technique: take Herba Epimedii, Radix Astragali car, front grass, Pollen Typhae and Radix Cyathulae and add water, decoct 2 times, 2 hours first times, second time 1 hour, merging filtrate, it is the extractum of 1.14-1.17 that filtrate is condensed into relative density when 60-70 DEG C, cooling, filtering, the starch airpillow-dry adding the amount of making 15% is granulated, and to obtain final product.
Specification: 5g/ bag.
Usage and dosage: oral, 10-15g, 2��3 times on the one, or follow the doctor's advice.
Function with cure mainly: treatment chronic atrophic gastritis and complication thereof.
Claims (8)
1. 'Qianlieshule ' application in preparation treatment chronic atrophic gastritis and complication medicine thereof.
2. apply as claimed in claim 1, it is characterised in that: described complication includes gastrorrhagia, anemia or gastric ulcer.
3. apply as claimed in claim 1 or 2, it is characterized in that: described 'Qianlieshule ' calculates according to composition by weight, is mainly made up of Herba Epimedii 90-110 part, Radix Astragali 40-60 part, Herba Plantaginis 40-60 part, Pollen Typhae 27.5-47.5 part and Radix Cyathulae 11.5-13.5 part.
4. apply as claimed in claim 3, it is characterised in that: described 'Qianlieshule ' calculates by weight, is mainly made up of Herba Epimedii 100 parts, the Radix Astragali 50 parts, Herba Plantaginis 50 parts, Pollen Typhae 37.5 parts and Radix Cyathulae 12.5 parts.
5. apply as claimed in claim 4, it is characterized in that: described 'Qianlieshule ' is prepared: take each medicine, add one or more pharmaceutically acceptable adjuvants, according still further to the conventional method of pharmaceutical field, prepare into acceptable dosage form in field of medicaments.
6. apply as claimed in claim 5, it is characterised in that: described dosage form includes oral formulations, ejection preparation or external preparation.
7. apply as claimed in claim 6, it is characterised in that: described oral formulations includes granule, oral liquid, capsule, pill or tablet.
8. apply as claimed in claim 7, it is characterized in that: the preparation method of described granule is: take Herba Epimedii, Radix Astragali car, front grass, Pollen Typhae and Radix Cyathulae and add water, decoct 2 times, 2 hours first times, second time 1 hour, merging filtrate, it is the extractum of 1.14-1.17 that filtrate is condensed into relative density when 60-70 DEG C, cooling, filters, the starch airpillow-dry adding the amount of making 15% is granulated, and to obtain final product.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510989298.8A CN105616753A (en) | 2015-12-25 | 2015-12-25 | Application of Qianlieshule preparation in preparation of drug for treating chronic atrophic gastritis and complications thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510989298.8A CN105616753A (en) | 2015-12-25 | 2015-12-25 | Application of Qianlieshule preparation in preparation of drug for treating chronic atrophic gastritis and complications thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105616753A true CN105616753A (en) | 2016-06-01 |
Family
ID=56032364
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510989298.8A Pending CN105616753A (en) | 2015-12-25 | 2015-12-25 | Application of Qianlieshule preparation in preparation of drug for treating chronic atrophic gastritis and complications thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105616753A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107648465A (en) * | 2017-11-06 | 2018-02-02 | 贵州拜特制药有限公司 | Application in the preparation treatment atrophic gastritis and complication medicine as one wishes of rejuvenating |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101028387A (en) * | 2006-03-02 | 2007-09-05 | 北京星昊嘉宇医药科技有限公司 | Oral solid preparation for treating chronic prostatic phlogosis and its production |
-
2015
- 2015-12-25 CN CN201510989298.8A patent/CN105616753A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101028387A (en) * | 2006-03-02 | 2007-09-05 | 北京星昊嘉宇医药科技有限公司 | Oral solid preparation for treating chronic prostatic phlogosis and its production |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107648465A (en) * | 2017-11-06 | 2018-02-02 | 贵州拜特制药有限公司 | Application in the preparation treatment atrophic gastritis and complication medicine as one wishes of rejuvenating |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101947284B (en) | Traditional Chinese medicinal composition for treating diabetes and preparation method thereof | |
| CN104162094A (en) | Traditional Chinese medicine composition for treating obese polycystic ovary syndrome, and medicinal preparation thereof | |
| CN102008650A (en) | Compound traditional Chinese medicine preparation for treating tumors and preparation method thereof | |
| CN109260369A (en) | A kind of composition and preparation method thereof and the application in prevention and treatment mammary gland disease | |
| CN105616753A (en) | Application of Qianlieshule preparation in preparation of drug for treating chronic atrophic gastritis and complications thereof | |
| CN106177268B (en) | It is a kind of to treat Chinese medicine composition of impotence and preparation method thereof | |
| CN104398733A (en) | Traditional Chinese medicine preparation for treating liver depression and qi stagnation type thyroid cancer | |
| CN106620349A (en) | Medicine composition for nourishing yin of lung and kidney, cooling blood and realizing hemostasis and preparation method of medicine composition | |
| CN103933475B (en) | A kind of pharmaceutical composition treating mammary gland fibroma and its production and use | |
| CN101947299B (en) | Medicinal composition for treating coronary heart disease | |
| CN104922528A (en) | Medicine composite for treating malignant pleural effusion and preparation method and purpose thereof | |
| CN104840864B (en) | A kind of Chinese medicine preparation for the treatment of infantile spleen deficiency type diarrhoea | |
| CN104189314B (en) | It is a kind of to treat the turbid pharmaceutical composition for checking card high fat of blood of phlegm | |
| CN106620045A (en) | Preparation method and application of 95% ethanol extract of clerodendrum japonicum roots | |
| CN107648465A (en) | Application in the preparation treatment atrophic gastritis and complication medicine as one wishes of rejuvenating | |
| CN106619870A (en) | Composition for treating digestive system neoplasms, and preparation method of composition | |
| CN102961677B (en) | Traditional Chinese medicine preparation for treating gallstone and cholecystitis and preparation method thereof | |
| CN102961680B (en) | Traditional Chinese medicine preparation for treating gallstone and cholecystitis and preparation method thereof | |
| CN106177347A (en) | A kind of pharmaceutical composition treating constipation | |
| CN105497251A (en) | Medicine composition for treating functional dyspepsia | |
| CN104587122A (en) | Traditional Chinese medicine composition for treating chronic gastritis | |
| CN118078939A (en) | Traditional Chinese medicine composition for treating chronic atrophic gastritis and preparation method thereof | |
| CN104606427A (en) | Schefflera arboricola-contained traditional Chinese medicinal composition | |
| CN104606426A (en) | Traditional Chinese medicinal composition preparation for treating chronic gastritis and preparation method thereof | |
| CN104491316A (en) | Traditional Chinese medicine preparation for treating middle-warmer energy insufficiency type prostate hyperplasia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160601 |
|
| RJ01 | Rejection of invention patent application after publication |